Breaking Finance News

Carl Zeiss Meditec (ETR:AFX) stock price target increased to 38.00EUR, issued a report today by Independent Research GmbH

Just yesterday Carl Zeiss Meditec (ETR:AFX) traded 0.00% even at 37.14EUR. Carl Zeiss Meditec’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.06% over the same time period. 0 shares of AFX traded hands, down from an average trading volume of 0

In a statement issued on 2/12/2017 Independent Research GmbH upped the price target of Carl Zeiss Meditec (ETR:AFX) to 38.00EUR reporting a possible upside of 0.02%.

Previously on 02/11/2017, Kepler Cheuvreux reported on Carl Zeiss Meditec (ETR:AFX) increased the target price from 0.00EUR to 38.00EUR. At the time, this indicated a possible upside of 0.02%.

Recent Performance Chart

Carl Zeiss Meditec (ETR:AFX)

Carl Zeiss Meditec has 52 week low of 0.00EUR and a 52 week high of 0.00EUR and has a market capitalization of 0 EUR.

Brief Synopsis On Carl Zeiss Meditec (ETR:AFX)

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.